Revance Therapeutics, Inc. is a biotechnology company specializing in the research, manufacturing, and marketing of neuromodulators for diverse aesthetic and therapeutic uses across both domestic and international markets. The company's leading product candidate, DaxibotulinumtoxinA for injection, has concluded Phase III clinical evaluations for treating glabellar (frown) lines and cervical dystonia. This same drug is currently in Phase II clinical trials for addressing upper facial lines, moderate to severe dynamic forehead lines, and moderate to severe lateral canthal lines, following the successful completion of its Phase II trials for adult upper limb spasticity and plantar fasciitis. Beyond this, Revance is conducting preclinical studies for DaxibotulinumtoxinA as a potential migraine treatment and is developing a topical version for various indications. The company is also developing OnabotulinumtoxinA, intended as a biosimilar to BOTOX. A collaborative and licensing partnership with Viatris Inc. facilitates the development, manufacturing, and commercialization of onabotulinumtoxinA. Initially established in 1999 as Essentia Biosystems, Inc., the company officially rebranded as Revance Therapeutics, Inc. in April 2005 and maintains its corporate headquarters in Nashville, Tennessee.